JP2023509484A - 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン - Google Patents

神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン Download PDF

Info

Publication number
JP2023509484A
JP2023509484A JP2022541634A JP2022541634A JP2023509484A JP 2023509484 A JP2023509484 A JP 2023509484A JP 2022541634 A JP2022541634 A JP 2022541634A JP 2022541634 A JP2022541634 A JP 2022541634A JP 2023509484 A JP2023509484 A JP 2023509484A
Authority
JP
Japan
Prior art keywords
disorder
dextromethadone
composition
administering
nmdar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022541634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509484A5 (https=
Inventor
パオロ・エル・マンフレーディ
チャールズ・イー・イントゥリッシ
サラ・デ・マルティン
アンドレア・マッタレイ
ヤコポ・ズグリニャーニ
アンドレア・カヴァリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Original Assignee
Institute for Research in Biomedicine IRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB filed Critical Institute for Research in Biomedicine IRB
Publication of JP2023509484A publication Critical patent/JP2023509484A/ja
Publication of JP2023509484A5 publication Critical patent/JP2023509484A5/ja
Priority to JP2026000511A priority Critical patent/JP2026062924A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
JP2022541634A 2020-01-03 2020-12-30 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン Pending JP2023509484A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026000511A JP2026062924A (ja) 2020-01-03 2026-01-05 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062956839P 2020-01-03 2020-01-03
US62/956,839 2020-01-03
US202062963874P 2020-01-21 2020-01-21
US62/963,874 2020-01-21
US202062993188P 2020-03-23 2020-03-23
US62/993,188 2020-03-23
US202063010391P 2020-04-15 2020-04-15
US63/010,391 2020-04-15
US202063031785P 2020-05-29 2020-05-29
US63/031,785 2020-05-29
PCT/US2020/067498 WO2021138443A1 (en) 2020-01-03 2020-12-30 Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026000511A Division JP2026062924A (ja) 2020-01-03 2026-01-05 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン

Publications (2)

Publication Number Publication Date
JP2023509484A true JP2023509484A (ja) 2023-03-08
JP2023509484A5 JP2023509484A5 (https=) 2024-02-05

Family

ID=76687448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022541634A Pending JP2023509484A (ja) 2020-01-03 2020-12-30 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン
JP2026000511A Pending JP2026062924A (ja) 2020-01-03 2026-01-05 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026000511A Pending JP2026062924A (ja) 2020-01-03 2026-01-05 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン

Country Status (12)

Country Link
US (1) US20230017786A1 (https=)
EP (1) EP4085044A4 (https=)
JP (2) JP2023509484A (https=)
KR (1) KR20220164470A (https=)
CN (1) CN115397804A (https=)
AU (1) AU2020419181A1 (https=)
BR (1) BR112022013160A2 (https=)
CA (1) CA3166254A1 (https=)
MX (1) MX2022007768A (https=)
TW (1) TW202140415A (https=)
UY (1) UY39007A (https=)
WO (1) WO2021138443A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119202724B (zh) * 2024-09-25 2025-05-30 宁夏医科大学总医院 一种脓毒症心肌病诊断模型的构建方法及诊断系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140088155A1 (en) * 2012-09-27 2014-03-27 Paolo L. Manfredi d-Methadone for the Treatment of Psychiatric Symptoms
US20150250733A1 (en) * 2012-10-15 2015-09-10 Isa Odidi Oral drug delivery formulations
US20180214395A1 (en) * 2017-01-31 2018-08-02 Paolo L. Manfredi Compounds for Treatment or Prevention of Disorders of the Nervous System and Symptoms and Manifestations Thereof, and for Cyto-Protection Against Diseases and Aging of Cells, and Symptoms and Manifestations Thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
CA3064846A1 (en) * 2017-05-25 2018-11-29 Glytech, Llc Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
EP3917619A4 (en) * 2019-01-30 2022-10-26 University of Padova Structurally modified opioids for prevention and treatment of diseases and conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140088155A1 (en) * 2012-09-27 2014-03-27 Paolo L. Manfredi d-Methadone for the Treatment of Psychiatric Symptoms
US20150250733A1 (en) * 2012-10-15 2015-09-10 Isa Odidi Oral drug delivery formulations
US20180214395A1 (en) * 2017-01-31 2018-08-02 Paolo L. Manfredi Compounds for Treatment or Prevention of Disorders of the Nervous System and Symptoms and Manifestations Thereof, and for Cyto-Protection Against Diseases and Aging of Cells, and Symptoms and Manifestations Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Trea", PR NEWSWIRE, JPN6025003674, 15 October 2019 (2019-10-15), ISSN: 0005677502 *

Also Published As

Publication number Publication date
US20230017786A1 (en) 2023-01-19
WO2021138443A1 (en) 2021-07-08
EP4085044A1 (en) 2022-11-09
MX2022007768A (es) 2022-09-27
BR112022013160A2 (pt) 2022-11-08
UY39007A (es) 2021-07-30
KR20220164470A (ko) 2022-12-13
EP4085044A4 (en) 2024-06-12
CN115397804A (zh) 2022-11-25
CA3166254A1 (en) 2021-07-08
JP2026062924A (ja) 2026-04-10
TW202140415A (zh) 2021-11-01
AU2020419181A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
Grieco et al. Psychedelics and neural plasticity: therapeutic implications
JP7679304B2 (ja) 非サイケデリック／精神異常発現性の投与量及び製剤で投与される神経可塑性作用を有する物質を含む組成物並びに使用方法
JP6245983B2 (ja) パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
Sani et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence
Jamesa et al. The insomnia-addiction positive feedback loop: role of the orexin system
US20130289061A1 (en) Methods and compositions to prevent addiction
JP2026062924A (ja) 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン
CN101374514A (zh) 神经元烟碱性受体配体和它们的用途
Yuen et al. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses
Suemaru et al. Antidepressant-like action of nicotine in forced swimming test and brain serotonin in mice
Morita et al. Plasma dehydroepiandrosterone sulfate levels in patients with major depressive disorder correlate with remission during treatment with antidepressants
Uyar et al. New and emerging pharmacologic treatments for MDD
EP3125902A2 (en) Use of negative modulators of gaba receptors containing alpha5 subunits as fast acting antidepressants
Kyzer et al. Classics in chemical neuroscience: buprenorphine
Cardona-Acosta et al. Alprazolam exposure during adolescence induces long-lasting dysregulation in reward sensitivity to morphine and second messenger signaling in the VTA-NAc pathway
Guan The role of trace amine-associated receptor 1 (TAAR1) in the pathophysiology and treatment of depression
Sotille et al. Unraveling the mysteries of mental illness with psilocybin
US20220112153A1 (en) Structurally modified opioids for prevention and treatment of diseases and conditions
JP2019510756A (ja) 常用癖又は物質使用障害を治療するための組成物と方法
Ivanov et al. Neurorobiology and evidence-based biological treatments for substance abuse disorders
US20240350433A1 (en) Treatment compositions and methods
Waldinger Future treatments of premature ejaculation
Aghadoukht et al. Role of opioid tapering in rescuing anxiety and social novelty deficits in morphine-withdrawn male rats
Annala TrkB and ERK signaling in the mechanism of NMDA receptor-blocking antidepressants
Siddiqui Cardiovascular Risk Factors Amongst Individuals with Schizophrenia Receiving General-Population Smoking Cessation Treatment: An Observational Study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260428